LUND, Sweden, Nov. 11, 2021 /PRNewswire/ -- Immunovia
has today published its report for the third quarter 2021. It is
available on Immunovia's website.
Patrik Dahlen, CEO:
"I am very pleased that we right from the start of the
commercialization of our blood test IMMray™ PanCan-d in the
USA have received so much positive
feedback from the pancreatic cancer community. The largest patient
organization with more than 1 million constituents, Pancreatic
Cancer Action Network (PanCAN), informed about our test underlining
that it is the first-ever blood test specific for pancreatic cancer
available to high risk individuals. This strong support is
important in achieving the prioritized goal for Immunovia: A
successful market penetration in the US market."
Investors, analysts and media are invited to a telephone
conference with web presentation today at 16:30 CEST. CEO Patrik
Dahlen will present Immunovia and comment on the interim
report followed by a Q&A session. The webcasted telephone
conference will be held in English.
To participate in the telephone conference, please
Sweden: +46 8 505 583
+44 333 300 92 73
+1 646 722 49 57
Belgium: +32 262 005
Denmark: +45 787 232
France: +33 170 750
+49 692 222 391 65
Norway: +47 239 636
+41 225 805 976
+31 207 219 496
Link to the
Following the telephone conference, a recording will be
available on Immunovia's website (www.immunovia.com).
For more information, please contact:
Patrik Dahlen, CEO Immunovia
Tel: +46 73 376 76 64
This information is information that Immunovia AB (publ) is
obliged to make public pursuant to the EU Market Abuse Regulation
and the Securities Markets Act. The information was submitted for
publication, through the agency of the contact person set out
above, at 16:00 CET on November
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer based on Immunovia's proprietary test platform
called IMMray™. Tests are based on antibody biomarker
microarray analysis using advanced machine-learning and
bioinformatics to single-out a set of relevant biomarkers that
indicate a certain disease. Thus, forming a unique "disease
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
high risk groups in pancreatic cancer, PanFAM-1, PanSYM-1 and
In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts, USA. The IMMray™
PanCan-d test, the first blood-based test dedicated to the early
detection of pancreatic cancer on the market, is offered as a
laboratory developed test (LDT) exclusively through Immunovia, Inc.
For more information see: www.immunoviainc.com.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
The following files are available for download:
Report, January-Sepember 2021
SOURCE Immunovia AB